Too long to read? Go for the highlights below. Compass Pathways accelerates its planned commercial launch of COMP360 for treatment-resistant depression by up to a year after favourable engagement with the FDA. Phase 3 data remain the decisive hurdle, with key 9-week and 26-week readouts expected in early 2026. Despite rising losses linked to warrant liability adjustments, the company reports a strengthened cash position sufficient to operate into 2027. Regulatory momentum and

Too long to read? Go for the highlights below.  Over 480 mushroom species across 126 genera have been identified in Africa, yet...

For decades, tissue engineering has relied on synthetic polymers, ceramics, and animal-derived collagen to support healing after injury....

In a discovery that blurs the line between plant and fungal metabolism, researchers from the University of Kurdistan and Université Laval...

A comprehensive study of ocean DNA has unveiled a plethora of fungi thriving in the twilight zone of the ocean, presenting promising...